A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

NCT05501912 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Adjustment of the applicant's research and development strategy

Conditions

Advanced Solid Tumor
BRAF V600 Mutation

Interventions

DRUG: ABM-1310

Sponsor

ABM Therapeutics Shanghai Company Limited